NCT02091063 - ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 2, 2014

Primary Completion Date

February 25, 2019

Study Completion Date

May 5, 2019

Conditions

LymphomaLymphoid Malignancies

Interventions

DRUG

ACY-1215

All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.

Trial Locations (2)

10019

Columbia University Medical Center, New York

33612

Moffit Cancer Center, Tampa